12/27/2013

Takeda Pharmaceutical has halted the development of its diabetes drug fasiglifam, saying the medication's benefits do not outweigh its possible risks. Fasiglifam was associated with liver damage in patients.

Full Story:
Bloomberg

Related Summaries